Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.
Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.
Company Details
- Employees
- 16
- Founded
- 2014
- Address
- 2450 Holcombe Blvd, Houston,texas,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- iteriontherapeutics.com
- HQ
- Houston, Texas
Iterion Therapeutics Questions
Iterion Therapeutics's website is iteriontherapeutics.com
Iterion Therapeutics's LinkedIn profile is https://www.linkedin.com/company/iterion-therapeutics
Iterion Therapeutics has
16 employees.
View email and phone details for 16
employees at Iterion Therapeutics.
Iterion Therapeutics's industry is
Biotechnology Research
Iterion Therapeutics's top competitors are
Ingeneron,
Avance Biosciences, Inc.,
Stingray Therapeutics,
March Biosciences,
Hope Biosciences,
Celltex Therapeutics Corporation,
Tvardi Therapeutics,
Salarius Pharmaceuticals,
Moleculin Biotech, Inc.,
Kiromic Biopharma, Inc..
Iterion Therapeutics's categories are Biotechnology Research
Iterion Therapeutics's founding year is 2014
